Page last updated: 2024-11-12

dc 88-a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

duocarmycin A: from a Streptomycete [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Duma	genus	[no description available]	Polygonaceae	The only family of the buckwheat order (Polygonales) of dicotyledonous flowering plants. It has 40 genera of herbs, shrubs, and trees.[MeSH]

Cross-References

ID Source	ID
PubMed CID	11762918
CHEMBL ID	161989
SCHEMBL ID	19493154
MeSH ID	M0162602

Synonyms (21)

Synonym
deuocarmycin a
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,4,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r-(6alpha,7br*,8aalpha))-
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,3,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r,7br,8as)-
dc88-a
duocarmycin a
CHEMBL161989
118292-34-5
pjv9990868 ,
unii-pjv9990868
dc-88a
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,4,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r-(6.alpha.,7br*,8a.alpha.))-
(+)-duocarmycin a
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,4,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r,7br,8as)-
AKOS027256705
duma
SCHEMBL19493154
DTXSID40922656
HY-12455
CS-0011399
Q27286591
methyl (1r,4r,12s)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" In vivo evaluation of the prodrug 6 showed that it exhibits extraordinary efficacy (T/C > 1500, L1210; 6/10 one year survivors), substantially exceeding that of the free drug, that its therapeutic window of activity is much larger, permitting a dosing ≥ 40-fold higher than the free drug, and yet that it displays a potency in vivo that approaches the free drug (within 3-fold)."	( Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs. Boger, DL; Brown, D; Duncan, KK; Parelkar, NK; Vielhauer, GA; Wolfe, AL, 2013)	0.39
" SYD983 could be dosed up to 30 mg/kg in cynomolgus monkeys with high exposure, excellent stability in blood, and without severe toxic effects."	( Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Beusker, P; Coumans, R; de Groot, V; de Roo, G; Dokter, W; Egging, D; Elgersma, R; Eppink, M; Groothuis, P; Huijbregts, T; Jacobs, D; Joosten, J; Loosveld, E; Mattaar, E; Menge, W; Spijker, H; Timmers, M; Ubink, R; van Achterberg, T; van den Dobbelsteen, D; van der Lee, M; van der Vleuten, M; Verheijden, G, 2014)	0.4

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (3.08)	18.7374
1990's	19 (29.23)	18.2507
2000's	20 (30.77)	29.6817
2010's	24 (36.92)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.19 (24.57)
Research Supply Index	4.25 (2.92)
Research Growth Index	5.44 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.19)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	5 (7.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	64 (92.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.69	3	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
carbamates [no description available]	2.07	1	amino-acid anion
phenol [no description available]	2.1	1	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
stallimycin [no description available]	3.09	5
cyclopropane cyclopropane : A cycloalkane composed of three carbon atoms to form a ring.	2.1	1	cycloalkane; cyclopropanes	inhalation anaesthetic
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	5.3	17	pyrrole; secondary amine
bromine Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.	1.97	1	diatomic bromine
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	1.97	1	diatomic chlorine; gas molecular entity	bleaching agent
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.18	1	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
9-methyladenine 9-methyladenine : Adenine substituted with a methyl group at position N-9.	2.02	1	methyladenine	metabolite
duocarmycin sa duocarmycin SA: structure similar to CC-1065 and yatakemycin, composed of a pyrrolo-indole plus an indole; isolated from Streptomyces	5.04	13
pyrindamycin a pyrindamycin A: isolated from Streptomyces sp. SF2582	4.19	5
duocarmycin b2 duocarmycin B2: from Streptomyces sp. DO-89	4.34	6
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	3.18	1	divalent inorganic anion; phosphite ion
glycosides [no description available]	2.05	1
maytansine Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.	3.06	1	alpha-amino acid ester; carbamate ester; epoxide; maytansinoid; organic heterotetracyclic compound; organochlorine compound	antimicrobial agent; antimitotic; antineoplastic agent; plant metabolite; tubulin modulator
zinostatin Zinostatin: An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic.	1.98	1
diamide Diamide: A sulfhydryl reagent which oxidizes sulfhydryl groups to the disulfide form. It is a radiation-sensitizing agent of anoxic bacterial and mammalian cells.	2.01	1	1,1'-azobis(N,N-dimethylformamide)
kapurimycin a3 kapurimycin A3: structure given in first source; isolated from a Streptomyces sp.	2.38	2
du 86 DU 86: structure given in first source	1.98	1
cc 1065 CC 1065: from Streptomyces zelensis; structure in second sourc	6.28	15
duocarmycin b1 duocarmycin B1: from Streptomyces sp. DO-89	4.99	7
guanine [no description available]	2.39	2	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite

Condition	Relationship Strength	Studies
Epithelial Ovarian Cancer [description not available]	3.06	1
Epithelial Neoplasms [description not available]	3.06	1
Cancer of Ovary [description not available]	3.47	2
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	3.06	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.47	2
Breast Cancer [description not available]	2.54	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.54	2
Leukemia L 1210 [description not available]	3.85	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.13	1
Cancer of the Uterus [description not available]	2.13	1
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.13	1
Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)	2.13	1
Benign Neoplasms [description not available]	4.23	6
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.23	6
Malignant Melanoma [description not available]	2.05	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.05	1
Anoxemia [description not available]	2.06	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.06	1
B16 Melanoma [description not available]	2.4	2
Cancer of Lung [description not available]	2.03	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.03	1
Sarcoma 180 An experimental sarcoma of mice.	2.39	2
Experimental Neoplasms [description not available]	2	1

chemdatabank.com